stockrow
Friday 6 November 2026
Export PVLA’s income statement to Excel — free account
Palvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
174.08
17.23
+10.99%
Follow PVLA
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 4 | 5 | 1 | 3 | 2 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
10.44 | 13.47 | 4.85 | 3.96 | 4.64 | 7.77 | 3.12 | 0.62 | — | — |
Altman Z-Score |
(1.67) | 0.82 | (0.39) | (0.06) | (1.89) | (1.23) | (4.34) | (11.49) | — | — |
Altman Z″-Score (non-manufacturers) |
(6.67) | (1.81) | (0.39) | (0.62) | (4.95) | (3.92) | (10.01) | (39.37) | — | — |
P/FCF ratio |
0.00 | 7.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Beneish M-Score |
— | 64.79 | (4.28) | 2.46 | (2.97) | (3.16) | 1.44 | — | — | — |
P/Operating CF |
(9.05) | (72.53) | (15.59) | (13.11) | (10.15) | (22.29) | (6.25) | 1.29 | — | — |
P/B ratio |
2.41 | 29.55 | 3.54 | 3.57 | 4.39 | 4.81 | 2.89 | 0.00 | — | — |
Price to Tangible BV |
2.41 | 29.55 | 3.54 | 3.57 | 4.39 | 4.81 | 2.89 | 0.00 | — | — |
EV/Sales |
5.63 | 10.65 | 0.49 | 1.74 | 2.29 | 4.06 | 0.89 | 0.47 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.64 | — | — |
EV/Operating CF |
(2.28) | 5.41 | (13.47) | (1.53) | (1.46) | (16.64) | (0.38) | (1.48) | — | — |
EV/FCF |
(2.20) | 5.63 | (5.19) | (1.46) | (1.38) | (14.81) | (0.38) | (1.46) | — | — |
Quick Ratio |
3.51 | 1.93 | 2.72 | 4.11 | 3.26 | 2.39 | 1.92 | 5.67 | 7.14 | 5.11 |
Current Ratio |
3.90 | 1.96 | 2.82 | 4.26 | 3.42 | 2.52 | 2.01 | 3.20 | 7.33 | 5.20 |
Net Debt/EBITDA |
1.31 | 5.11 | 4.23 | 3.93 | 2.23 | 2.39 | 1.45 | 0.62 | 5.93 | 1.50 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.17 | 0.36 | 0.24 | 0.33 | 0.24 | 0.24 | 0.21 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.63 | (2.82) | 0.04 | 1.85 | 1.23 | 0.17 | 1.80 | (0.76) | 0.62 | 0.60 |
Capex/Depreciation |
(1.55) | (5.28) | (2.98) | (3.90) | (1.18) | (0.39) | (0.38) | 0.00 | — | — |
Interest Coverage |
11,379.50 | 96.01 | (15.71) | (15.84) | (66.38) | (12,957.75) | (60.30) | 1.89 | (3.26) | (6.63) |
| (80.91%) | (96.04%) | (103.99%) | (62.00%) | (90.39%) | (111.85%) | (84.58%) | (76.96%) | 293.60% | (92.10%) | |
| (66.07%) | (25.40%) | (21.82%) | (20.04%) | (30.26%) | (35.38%) | (26.72%) | 34.77% | (36.40%) | (56.45%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(85.85%) | (36.73%) | (28.97%) | (26.32%) | (49.23%) | (47.55%) | (61.82%) | 345.32% | (22.88%) | (87.56%) |
Average Days of Receivables |
3.57 | 224.50 | 33.88 | 53.53 | 21.24 | 38.49 | 155.61 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
337.83% | 88.17% | 142.57% | 118.84% | 158.68% | 212.16% | 204.55% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
152.48% | 69.57% | 63.37% | 39.85% | 57.00% | 52.81% | 63.29% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
32.67% | 12.05% | 16.99% | 11.61% | 17.36% | 16.60% | 16.99% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.38 | (0.01) | 0.24 | 0.14 | 0.01 | 0.10 | 0.07 | (0.15) | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 145.62 | — | — |
Earnings Yield |
(36.99%) | (5.29%) | (18.56%) | (16.57%) | (27.20%) | (18.25%) | (41.28%) | (150.54%) | — | — |
Free Cash Flow Yield |
(24.55%) | 14.04% | (1.96%) | (29.97%) | (35.70%) | (3.53%) | (75.41%) | (52.67%) | — | — |
Revenue per Share |
11.18 | 46.03 | 43.86 | 73.13 | 43.06 | 38.94 | 27.94 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(27.59) | 90.61 | (1.61) | (82.91) | (67.39) | (9.49) | (64.64) | (7.74) | (4.87) | (2.22) |
Capex per Share |
(1.07) | (3.55) | (2.56) | (3.89) | (4.00) | (1.18) | (1.12) | (0.10) | 0.00 | 0.00 |
Free Cash Flow per Share |
(28.67) | 87.06 | (4.17) | (86.80) | (71.40) | (10.67) | (65.76) | (7.84) | (4.87) | (2.22) |
Cash per Share |
56.30 | 132.27 | 193.08 | 164.59 | 103.43 | 145.96 | 63.81 | 4.15 | 37.56 | 5.15 |
Shareholders Equity per Share |
48.38 | 20.98 | 60.19 | 81.15 | 45.56 | 62.91 | 30.12 | (2.19) | 28.13 | 2.49 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
48.38 | 20.98 | 60.19 | 81.15 | 45.56 | 62.91 | 30.12 | (2.19) | 28.13 | 2.49 |
Free Cash Flow |
(14.95) | 47.80 | (2.76) | (54.93) | (48.62) | (8.61) | (60.97) | (13.87) | (10.84) | (25.01) |
Working Capital |
24.29 | 44.02 | 87.31 | 88.01 | 53.58 | 77.06 | 36.84 | 5.19 | 76.20 | 47.64 |
Capital Expenditures |
(0.56) | (1.95) | (1.70) | (2.46) | (2.73) | (0.95) | (1.04) | (0.17) | — | — |
Net Current Asset Value |
22.84 | (2.56) | 33.98 | 25.27 | 1.74 | 24.82 | 5.86 | (3.88) | 62.61 | 27.41 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.10 | 0.08 | 0.06 | 0.05 | 0.09 | 0.03 | 0.04 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.89 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.16 | 0.09 | 0.11 | 0.03 | 0.10 | 0.13 | 0.16 | 0.00 | — | — |
Cash ROIC |
(27.39%) | 56.81% | (1.64%) | (35.32%) | (47.92%) | (5.11%) | (70.01%) | (399.83%) | (7.41%) | (29.09%) |
Accounts Receivable Turnover |
19.27 | 3.24 | 3.19 | 9.76 | 6.91 | 12.52 | 3.61 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.30 | 7.80 | 9.12 | 4.74 | 4.25 | 2.51 | 7.18 | 8.54 | 4.19 | — |
Average Payables |
1.72 | 2.42 | 2.90 | 4.58 | 3.80 | 5.20 | 6.38 | 2.55 | 2.76 | 4.59 |
Average Assets |
34.51 | 69.47 | 122.61 | 141.22 | 123.05 | 129.29 | 124.53 | 51.52 | 47.89 | 73.90 |
Average Common Equity |
28.18 | 18.37 | 25.73 | 45.64 | 41.19 | 40.89 | 39.34 | (23.28) | (5.94) | 45.30 |
Columns are period end dates · fundamentals updated 26 Oct 2026